PMID- 19727937
OWN - NLM
STAT- MEDLINE
DCOM- 20100301
LR  - 20221207
IS  - 1432-086X (Electronic)
IS  - 0174-1551 (Linking)
VI  - 32
IP  - 6
DP  - 2009 Nov
TI  - OEM-TACE: a new therapeutic approach in unresectable intrahepatic 
      cholangiocarcinoma.
PG  - 1187-92
LID - 10.1007/s00270-009-9694-4 [doi]
AB  - Intrahepatic cholangiocarcinoma (ICC) is a rare life-threatening disease, whose 
      only treatment with potential for cure is surgical resection. However, only 27% 
      of patients at most are suitable for surgery when first diagnosed. For patients 
      with unresectable disease, therapeutic options are chemotherapy or 
      chemoradiation. We evaluated the feasibility and safety of oxaliplatin-eluting 
      microspheres transarterial chemoembolization (OEM-TACE) associated with 
      chemotherapy (ChT) in patients affected by unresectable ICC. Between December 
      2005 and May 2008 we treated nine patients (six female and three male) with 
      unresectable ICC. All patients had undergone OEM-TACE associated with 
      chemotherapy with oxaliplatin and gemcitabine. A retrospective comparison was 
      carried out with a historical group of 11 patients treated with ChT only, 
      estimating the prevalence of adverse effects and the median survival of the two 
      groups. A total of 30 TACEs were performed during the observational time (ranging 
      from one to seven procedures per patient). OEM-TACEs were followed by few adverse 
      effects (AEs), without G4 AEs, according to CTACAE 3.0. According to RECIST 
      criteria, 44% (4/9) of patients achieved partial responses and 56% (5/9) 
      stabilization of disease. Overall survival analysis in the two groups showed a 
      significantly increased survival in patients treated with ChT and OEM-TACE, with 
      respect to those treated with ChT (30 vs. 12.7 months; p=0.004). In conclusion, 
      in our experience OEM-TACE associated with ChT in the treatment of advanced 
      unresectable ICC is a safe and feasible treatment causing no major adverse 
      events. Although RECIST criteria can underestimate the rate of responses in 
      patients treated with locoregional therapies, we achieved very encouraging 
      results. A randomized multicentric trial is warranted to assess the actual 
      superiority of OEM-TACE associated with ChT compared to conventional 
      chemotherapy.
FAU - Poggi, Guido
AU  - Poggi G
AD  - Division of Medical Oncology II, Department of Interventional Radiology, IRCCS S. 
      Maugeri Foundation, Maugeri Street 10, 27100 Pavia, Italy. guido.poggi@fsm.it
FAU - Amatu, A
AU  - Amatu A
FAU - Montagna, B
AU  - Montagna B
FAU - Quaretti, P
AU  - Quaretti P
FAU - Minoia, C
AU  - Minoia C
FAU - Sottani, C
AU  - Sottani C
FAU - Villani, L
AU  - Villani L
FAU - Tagliaferri, B
AU  - Tagliaferri B
FAU - Sottotetti, F
AU  - Sottotetti F
FAU - Rossi, O
AU  - Rossi O
FAU - Pozzi, E
AU  - Pozzi E
FAU - Zappoli, F
AU  - Zappoli F
FAU - Riccardi, A
AU  - Riccardi A
FAU - Bernardo, G
AU  - Bernardo G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Intervent Radiol
JT  - Cardiovascular and interventional radiology
JID - 8003538
RN  - 0 (Organoplatinum Compounds)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Aged
MH  - Bile Duct Neoplasms/*therapy
MH  - *Bile Ducts, Intrahepatic
MH  - Chemoembolization, Therapeutic/*methods
MH  - Cholangiocarcinoma/*therapy
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Microspheres
MH  - Organoplatinum Compounds/administration & dosage
MH  - Oxaliplatin
MH  - Palliative Care
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Gemcitabine
EDAT- 2009/09/04 06:00
MHDA- 2010/03/02 06:00
CRDT- 2009/09/04 06:00
PHST- 2009/03/09 00:00 [received]
PHST- 2009/07/22 00:00 [accepted]
PHST- 2009/09/04 06:00 [entrez]
PHST- 2009/09/04 06:00 [pubmed]
PHST- 2010/03/02 06:00 [medline]
AID - 10.1007/s00270-009-9694-4 [doi]
PST - ppublish
SO  - Cardiovasc Intervent Radiol. 2009 Nov;32(6):1187-92. doi: 
      10.1007/s00270-009-9694-4.